Giuseppe Ciaramella - 03 Jan 2023 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role: President & CSO
Signature: By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol: BEAM
Transactions as of: 03 Jan 2023
Net transactions value: -$1,961,135
Form type: 4
Filing time: 05 Jan 2023, 15:06:47 UTC
Previous filing: 03 Jan 2023
Next filing: 31 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BEAM	Common Stock	Options Exercise	$6,101	+9,106	+9.5%	$0.6700^*	105,068	03 Jan 2023	Direct
transaction	BEAM	Common Stock	Options Exercise	$18,256	+4,326	+4.1%	$4.22^*	109,394	03 Jan 2023	Direct
transaction	BEAM	Common Stock	Options Exercise	$26,999	+40,297	+37%	$0.6700^*	149,691	03 Jan 2023	Direct
transaction	BEAM	Common Stock	Sale	$1,393,678	-37,525	-25%	$37.14	112,166	03 Jan 2023	Direct	F1, F2
transaction	BEAM	Common Stock	Sale	$520,615	-13,704	-12%	$37.99	98,462	03 Jan 2023	Direct	F1, F3
transaction	BEAM	Common Stock	Sale	$74,233	-1,900	-1.9%	$39.07	96,562	03 Jan 2023	Direct	F1, F4
transaction	BEAM	Common Stock	Sale	$23,964	-600	-0.62%	$39.94	95,962	03 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BEAM	Stock Option (Right to Buy)	Options Exercise	$0	-9,106	-100%	$0.000000^*	0	03 Jan 2023	Common Stock	9,106	$0.6700	Direct	F5
transaction	BEAM	Stock Option (Right to Buy)	Options Exercise	$0	-4,326	-100%	$0.000000^*	0	03 Jan 2023	Common Stock	4,326	$4.22	Direct	F5
transaction	BEAM	Stock Option (Right to Buy)	Options Exercise	$0	-40,297	-21%	$0.000000	150,905	03 Jan 2023	Common Stock	40,297	$0.6700	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.66 to $37.65, inclusive. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.66 to $38.48, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.82 to $39.75, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5	The option award vested upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.
F6	The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.